26 March 2018 - Acorda Therapeutics today announced that it has submitted a marketing authorisation application to the EMA for Inbrija. Acorda is seeking marketing approval in the European Union for Inbrija, an investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen.

The application for Ibrija includes clinical data from the Inbrija Phase 3 safety and efficacy trial (SPAN-PD), as well as the results from two long-term safety studies in people with Parkinson’s. Findings from these studies support the submission of Inbrija for use on an as needed basis to address symptoms of OFF periods. The primary endpoint from the Phase 3 study of Inbrija showed a statistically significant improvement in motor function in people with Parkinson’s disease experiencing OFF periods.

The U.S. FDA is currently reviewing a new drug application for Inbrija and has set an action date of 5 October 2018 under the Prescription Drug User Fee Act.

Read Acorda Therapeutics press release